Cancer Treatment Reviews
Volume 31 , Pages S17-S25 , 2005

Case studies of fulvestrant (‘Faslodex’) in postmenopausal women with advanced breast cancer

  • Paul Abram

      Affiliations

    • Belvoir Park Hospital, Hospital Road, Belfast, Northern Ireland, UK
    • Corresponding Author InformationCorresponding author. Tel.: + 44 2890 699 323; fax: + 44 2890 699 406.
    • ,
  • Nicolai Maass

      Affiliations

    • University of Kiel, Kiel, Germany
    • ,
  • Daniel Rea

      Affiliations

    • QEII Hospital, Birmingham, UK
    • ,
  • Sergio D. Simon

      Affiliations

    • Hospital Albert Einstein, São Paulo, Brazil
    • ,
  • Guenther G. Steger

      Affiliations

    • University of Vienna, Vienna, Austria

References 

  1. Chung CT, Carlson RW. Goals and objectives in the management of metastatic breast cancer. Oncologist. 2003;8:514–520
  2. Harmsen HJ, Porsius AJ. Endocrine therapy of breast cancer. Eur J Cancer Clin Oncol. 1988;24:1099–1116
  3. Robertson JF, Dixon AR, Nicholson RI, Ellis IO, Elston CW, Blamey RW. Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy. Breast Cancer Res Treat. 1992;22:221–227
  4. Curigliano G, Rigo R, Colleoni M, et al. Adjuvant therapy for very young women with breast cancer: response according to biologic and endocrine features. Clin Breast Cancer. 2004;5:125–130
  5. Menard S, Casalini P, Campiglio M, Pupa SM, Tagliabue E. Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci. 2004;61:2965–2978
  6. Robertson JFR. Incidence of polypharmacy in patients with breast cancer. The Breast. 2005;14:S39
  7. Robertson JFR. Incidence of polypharmacy in patients with breast cancer. In: Poster presentation at the Ninth International Conference on Primary Therapy of Breast Cancer, 26–29 January 2005, St. Gallen, Switzerland (poster 83).
  8. Fallowfield L, Atkins L, Morris R, et al. Routes of administration in breast cancer: preliminary findings from a patient survey. The Breast. 2005;14(Suppl. 1):S51;(abstr P126)
  9. Fallowfield L, Atkins L, Morris R, et al. Routes of administration in breast cancer: preliminary findings from a patient survey. In: Poster presentation at the Ninth International Conference on Primary Therapy of Breast Cancer, 26–29 January 2005, St Gallen, Switzerland (poster 126).
  10. Howell A, Robertson JFR, Quaresma AJ, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002;20:3396–3403
  11. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002;20:3386–3395
  12. Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women – a prospective combined analysis of two multicenter trials. Cancer. 2003;98:229–238
  13. Mauriac L, Pippen JE, Quaresma AJ, Gertler SZ, Osborne CK. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer. 2003;39:1228–1233
  14. Ingle JN, Rowland KM, Suman VJ, et al. Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: a phase II trial of the North Central Cancer Treatment Group. Breast Cancer Res Treat. 2004;88(Suppl. 1):S38;(abstr 409)
  15. Perey L, Paridaens R, Nolé F, et al. Fulvestrant (Faslodex™) as hormonal treatment in postmenopausal patients with advanced breast cancer (ABC) progressing after treatment with tamoxifen and aromatase inhibitors: update of a phase II SAKK trial. Breast Cancer Res Treat. 2004;88(Suppl. 1):S236;(abstr 6048)
  16. Steger G, Bartsch R, Wenzel C, et al. Fulvestrant (Faslodex®) in metastatic breast cancer. Breast Cancer Res Treat. 2003;82(Suppl. 1):S104;(abstr 437)
  17. Franco S, Perez A, Tan-Chiu E, Frankel C, Vogel CL. Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience. Breast Cancer Res Treat. 2004;88:103–108
  18. Petruzelka L, Zimovjanova M, Konopasek B, Mares P, Dlouha Z. Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy – updated results from an expanded access programme. Ann Oncol. 2004;15(Suppl. 3):iii36;(abstr 136P)
  19. Jones SE, Pippen J, Webster A. A retrospective analysis of the proportion of patients responding for >1, 1.5 and 2 years in two phase III studies of fulvestrant versus anastrozole. Breast Cancer Res Treat. 2004;88(Suppl. 1):S236;(abstr 6047)
  20. Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer. 1999;79:1220–1226
  21. Dowsett M, Harper-Wynne C, Boeddinghaus I, et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res. 2001;61:8452–8458
  22. Menard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene. 2003;22:6570–6578
  23. Howell A. The future of fulvestrant (‘Faslodex’). Cancer Treatment Rev. 2005;31(Suppl. 2):S26–S33

PII: S0305-7372(05)00142-8

doi: 10.1016/j.ctrv.2005.08.008

Cancer Treatment Reviews
Volume 31 , Pages S17-S25 , 2005

Article Tools

* Image Usage & Resolution